Sjögren's syndrome

Sjögren's syndrome is a chronic autoimmune disorder characterized by inflammation of the exocrine glands, particularly the salivary glands and lacrimal glands. This condition is named after Henrik Sjögren, a Swedish ophthalmologist who first described it in 1933. Sjögren's syndrome can occur as a standalone condition, known as primary Sjögren's syndrome, or in association with other autoimmune disorders, such as rheumatoid arthritis and lupus erythematosus. The exact prevalence of Sjögren's syndrome is unknown, but it is estimated to affect approximately 0.5-1% of the general population.

Signs and symptoms

The primary symptoms of Sjögren's syndrome are dry eyes (xerophthalmia) and dry mouth (xerostomia), which result from the inflammation and destruction of the lacrimal and salivary glands. Patients may experience keratoconjunctivitis sicca, a condition characterized by inflammation of the conjunctiva and cornea, leading to eye pain, blurred vision, and increased risk of cataracts and glaucoma. Dry mouth can lead to difficulties with swallowing, dysgeusia (altered taste), and increased risk of tooth decay and periodontal disease. Other symptoms may include fatigue, joint pain, and Raynaud's phenomenon.

Causes and pathophysiology

The exact causes of Sjögren's syndrome are unknown, but it is believed to result from a combination of genetic, environmental, and hormonal factors. Research suggests that T cells play a key role in the pathogenesis of Sjögren's syndrome, with autoantibodies such as antinuclear antibodies and rheumatoid factor often present in patients. The major histocompatibility complex (MHC) genes, particularly HLA-DRB1 and HLA-DQB1, have been associated with an increased risk of developing Sjögren's syndrome.

Diagnosis

The diagnosis of Sjögren's syndrome is based on a combination of clinical symptoms, laboratory tests, and imaging studies. The Schirmer's test and Rose Bengal staining are commonly used to assess tear production and detect keratoconjunctivitis sicca. Salivary gland biopsy and sialography may also be used to evaluate salivary gland function. Laboratory tests, including complete blood count, erythrocyte sedimentation rate, and C-reactive protein, may reveal signs of inflammation. Autoantibody testing, such as antinuclear antibody and rheumatoid factor, can also support the diagnosis.

Treatment

Treatment for Sjögren's syndrome focuses on managing symptoms and preventing complications. Artificial tears and salivary substitutes can help alleviate dry eyes and mouth. Restasis and Pilocarpine are medications that can increase tear and saliva production. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may be used to manage pain and inflammation. In some cases, immunomodulatory therapy, such as rituximab, may be necessary to control disease activity.

Epidemiology

Sjögren's syndrome can affect individuals of all ages, but it typically affects women more frequently than men, with a female-to-male ratio of approximately 9:1. The condition can occur at any age, but it most commonly affects individuals between the ages of 40 and 60. Sjögren's syndrome has been associated with an increased risk of lymphoma, particularly mucosa-associated lymphoid tissue (MALT) lymphoma.

Prognosis and complications

The prognosis for individuals with Sjögren's syndrome varies depending on the severity of symptoms and the presence of complications. Some patients may experience mild symptoms, while others may develop significant morbidity and mortality. Complications of Sjögren's syndrome can include vision loss, dental problems, and lymphoma. Patients with Sjögren's syndrome are also at increased risk of developing interstitial lung disease and renal disease. Regular monitoring and follow-up with a healthcare provider are essential to manage symptoms and prevent complications. Henrik Sjögren's work laid the foundation for our understanding of this complex condition, and ongoing research continues to uncover new insights into its causes and treatment.